Storia in 5 fonti

NewLimit triples valuation to $3B with $435M funding round

NewLimit, co-founded by Coinbase CEO Brian Armstrong, raises $435M at a $3.1B valuation for its epigenetic reprogramming approach to reversing aging.

Raccontata da

Confronto fonti

5 prospettive sulla stessa storia

AI · summaries

cryptobriefing.comStai leggendo1 mesi fa

NewLimit triples valuation to $3B with $435M funding round

NewLimit, co-founded by Coinbase CEO Brian Armstrong, raises $435M at a $3.1B valuation for its epigenetic reprogramming approach to reversing aging.

originale

news.bitcoin.com1 mesi fa

Coinbase CEO Brian Armstrong's Newlimit Raises $435 Million, Tripling Valuation to $3.1 Billion

Newlimit (biotech Armstrong/Coinbase) chiude Series C $435M, valutazione $3.1B triplicata. Longevity biotech attrae capital massiccio da crypto: aging-reversal diventa frontier seria per tech stack/budget decisions, human trials 2026.

Leggi questa versione → originale

qz.com1 mesi fa

NewLimit raises $435M Series C, valuation hits $3.1B

The South San Francisco biotech plans to begin its first human trial of a liver cell-reprogramming therapy next year

Leggi questa versione → originale

endpoints.news1 mesi fa

Anti-aging startup NewLimit raises $435M at $3B+ valuation, eyes clinic in 2027

NewLimit said Tuesday it has raised a $435 million Series C round at a $3.1 billion post-money valuation.

Leggi questa versione → originale

statnews.com1 mesi fa

Longevity startup NewLimit raises $435 million ahead of first clinical trial

Longevity startup NewLimit plans to launch its first clinical trial of a liver medicine after raising a staggering $435 million in new funding.

Leggi questa versione → originale

Timeline cronologica

martedì 2 giugno 2026·statnews.com
Longevity startup NewLimit raises $435 million ahead of first clinical trial
Longevity startup NewLimit plans to launch its first clinical trial of a liver medicine after raising a staggering $435 million in new funding.
martedì 2 giugno 2026·endpoints.news
Anti-aging startup NewLimit raises $435M at $3B+ valuation, eyes clinic in 2027
NewLimit said Tuesday it has raised a $435 million Series C round at a $3.1 billion post-money valuation.
martedì 2 giugno 2026·cryptobriefing.com
NewLimit triples valuation to $3B with $435M funding round
NewLimit, co-founded by Coinbase CEO Brian Armstrong, raises $435M at a $3.1B valuation for its epigenetic reprogramming approach to reversing aging.
mercoledì 3 giugno 2026·news.bitcoin.com
Coinbase CEO Brian Armstrong's Newlimit Raises $435 Million, Tripling Valuation to $3.1 Billion
NewLimit, co-founded by Coinbase CEO Brian Armstrong, raised a $435 million Series C led by Founders Fund, tripling its valuation to $3.1 billion.
mercoledì 3 giugno 2026·qz.com
NewLimit raises $435M Series C, valuation hits $3.1B
The South San Francisco biotech plans to begin its first human trial of a liver cell-reprogramming therapy next year